Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)

[...]as the MERS-CoV progressed overtime there was more identification of asymptomatic individuals due to increased surviellance and contacts testing. Asymptomatic carriage of influenza virus was estimated to be 5.2%–35.5% [4] Based on serology, the positivity rate was 13% in asymptomatic SARS 4% in...

Full description

Saved in:
Bibliographic Details
Published in:Travel medicine and infectious disease 2020-05, Vol.35, p.101608-101608, Article 101608
Main Author: Al-Tawfiq, Jaffar A.
Format: Article
Language:English
Subjects:
Betacoronavirus
Coronavirus Infections
Coronaviruses
COVID-19
Disease transmission
Families & family life
Humans
Infections
Infectious diseases
Middle East respiratory syndrome
Middle East Respiratory Syndrome Coronavirus
Pandemics
Pathogens
Pneumonia, Viral
Respiratory diseases
SARS Virus
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Symptoms
Travel medicine
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3
cites cdi_FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3
container_end_page 101608
container_issue
container_start_page 101608
container_title Travel medicine and infectious disease
container_volume 35
creator Al-Tawfiq, Jaffar A.
description [...]as the MERS-CoV progressed overtime there was more identification of asymptomatic individuals due to increased surviellance and contacts testing. Asymptomatic carriage of influenza virus was estimated to be 5.2%–35.5% [4] Based on serology, the positivity rate was 13% in asymptomatic SARS 4% in those with mild symptoms, and 82% in those with severe disease [5]. Since the emergence of SARS-COV-2, (known initially as 2019-nCoV), in Wuhan, China, in December 2019, the number of global cases had increased significantly. [...]studies will enhance the understanding of the pathogenesis of these emerging viruses and will inform policy makers to make scientifically sound recommendations.Funding source None.CRediT authorship contribution statement Jaffar A. Al-Tawfiq: Conceptualization, Writing - original draft.Declaration of competing interest None.
doi_str_mv 10.1016/j.tmaid.2020.101608
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7102602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1477893920300752</els_id><sourcerecordid>2425684896</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3</originalsourceid><addsrcrecordid>eNp9kV1LHDEUhkOxVKv9BQUZ8Ga9mDXfHwWFZf2oYBG09TZkM5k2y06yJjML_vtGR8V6UQgkJ3nPm3POA8BXBKcIIn60nPad8c0UQzzeQPkB7CApSA0pxVvlTIWopSJqG3zOeQkhYZKST2CbYIQoFGwHnM_yQ7fuY2d6bysbUwxm49OQKx9aZ3sfw7fqx9nNbT2Pd5UJTXU7G4MaV5P59d3laY3U4R742JpVdl-e913w6_zs5_x7fXV9cTmfXdWWMdLXrTSiJQ1vOMcCEccVQlKxFkPrFhxJSJVCTJKFoKzUhyDBrTWICWGssa4hu-Bk9F0Pi8411oU-mZVeJ9-Z9KCj8frfl-D_6N9xo4sX5hAXg8mzQYr3g8u97ny2brUywcUha0y4khKVVaQH76TLOKRQ2tOYYsYllYoXFRlVNsWck2tfi0FQP1LRS_3EST9y0iOnkrX_to_XnBcwRXA8ClyZ5sa7pLP1LpQZ-FSw6Cb6_37wFzACoQk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425684896</pqid></control><display><type>article</type><title>Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)</title><source>Elsevier</source><creator>Al-Tawfiq, Jaffar A.</creator><creatorcontrib>Al-Tawfiq, Jaffar A.</creatorcontrib><description>[...]as the MERS-CoV progressed overtime there was more identification of asymptomatic individuals due to increased surviellance and contacts testing. Asymptomatic carriage of influenza virus was estimated to be 5.2%–35.5% [4] Based on serology, the positivity rate was 13% in asymptomatic SARS 4% in those with mild symptoms, and 82% in those with severe disease [5]. Since the emergence of SARS-COV-2, (known initially as 2019-nCoV), in Wuhan, China, in December 2019, the number of global cases had increased significantly. [...]studies will enhance the understanding of the pathogenesis of these emerging viruses and will inform policy makers to make scientifically sound recommendations.Funding source None.CRediT authorship contribution statement Jaffar A. Al-Tawfiq: Conceptualization, Writing - original draft.Declaration of competing interest None.</description><identifier>ISSN: 1477-8939</identifier><identifier>EISSN: 1873-0442</identifier><identifier>DOI: 10.1016/j.tmaid.2020.101608</identifier><identifier>PMID: 32114075</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Betacoronavirus ; Coronavirus Infections ; Coronaviruses ; COVID-19 ; Disease transmission ; Families &amp; family life ; Humans ; Infections ; Infectious diseases ; Middle East respiratory syndrome ; Middle East Respiratory Syndrome Coronavirus ; Pandemics ; Pathogens ; Pneumonia, Viral ; Respiratory diseases ; SARS Virus ; SARS-CoV-2 ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Symptoms ; Travel medicine ; Viruses</subject><ispartof>Travel medicine and infectious disease, 2020-05, Vol.35, p.101608-101608, Article 101608</ispartof><rights>2020 Elsevier Ltd</rights><rights>2020. Elsevier Ltd</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3</citedby><cites>FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32114075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Tawfiq, Jaffar A.</creatorcontrib><title>Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)</title><title>Travel medicine and infectious disease</title><addtitle>Travel Med Infect Dis</addtitle><description>[...]as the MERS-CoV progressed overtime there was more identification of asymptomatic individuals due to increased surviellance and contacts testing. Asymptomatic carriage of influenza virus was estimated to be 5.2%–35.5% [4] Based on serology, the positivity rate was 13% in asymptomatic SARS 4% in those with mild symptoms, and 82% in those with severe disease [5]. Since the emergence of SARS-COV-2, (known initially as 2019-nCoV), in Wuhan, China, in December 2019, the number of global cases had increased significantly. [...]studies will enhance the understanding of the pathogenesis of these emerging viruses and will inform policy makers to make scientifically sound recommendations.Funding source None.CRediT authorship contribution statement Jaffar A. Al-Tawfiq: Conceptualization, Writing - original draft.Declaration of competing interest None.</description><subject>Betacoronavirus</subject><subject>Coronavirus Infections</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease transmission</subject><subject>Families &amp; family life</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Middle East respiratory syndrome</subject><subject>Middle East Respiratory Syndrome Coronavirus</subject><subject>Pandemics</subject><subject>Pathogens</subject><subject>Pneumonia, Viral</subject><subject>Respiratory diseases</subject><subject>SARS Virus</subject><subject>SARS-CoV-2</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Symptoms</subject><subject>Travel medicine</subject><subject>Viruses</subject><issn>1477-8939</issn><issn>1873-0442</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kV1LHDEUhkOxVKv9BQUZ8Ga9mDXfHwWFZf2oYBG09TZkM5k2y06yJjML_vtGR8V6UQgkJ3nPm3POA8BXBKcIIn60nPad8c0UQzzeQPkB7CApSA0pxVvlTIWopSJqG3zOeQkhYZKST2CbYIQoFGwHnM_yQ7fuY2d6bysbUwxm49OQKx9aZ3sfw7fqx9nNbT2Pd5UJTXU7G4MaV5P59d3laY3U4R742JpVdl-e913w6_zs5_x7fXV9cTmfXdWWMdLXrTSiJQ1vOMcCEccVQlKxFkPrFhxJSJVCTJKFoKzUhyDBrTWICWGssa4hu-Bk9F0Pi8411oU-mZVeJ9-Z9KCj8frfl-D_6N9xo4sX5hAXg8mzQYr3g8u97ny2brUywcUha0y4khKVVaQH76TLOKRQ2tOYYsYllYoXFRlVNsWck2tfi0FQP1LRS_3EST9y0iOnkrX_to_XnBcwRXA8ClyZ5sa7pLP1LpQZ-FSw6Cb6_37wFzACoQk</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Al-Tawfiq, Jaffar A.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H95</scope><scope>H97</scope><scope>K9.</scope><scope>KB0</scope><scope>L.G</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200501</creationdate><title>Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)</title><author>Al-Tawfiq, Jaffar A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Betacoronavirus</topic><topic>Coronavirus Infections</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease transmission</topic><topic>Families &amp; family life</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Middle East respiratory syndrome</topic><topic>Middle East Respiratory Syndrome Coronavirus</topic><topic>Pandemics</topic><topic>Pathogens</topic><topic>Pneumonia, Viral</topic><topic>Respiratory diseases</topic><topic>SARS Virus</topic><topic>SARS-CoV-2</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Symptoms</topic><topic>Travel medicine</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Tawfiq, Jaffar A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Travel medicine and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Tawfiq, Jaffar A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)</atitle><jtitle>Travel medicine and infectious disease</jtitle><addtitle>Travel Med Infect Dis</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>35</volume><spage>101608</spage><epage>101608</epage><pages>101608-101608</pages><artnum>101608</artnum><issn>1477-8939</issn><eissn>1873-0442</eissn><abstract>[...]as the MERS-CoV progressed overtime there was more identification of asymptomatic individuals due to increased surviellance and contacts testing. Asymptomatic carriage of influenza virus was estimated to be 5.2%–35.5% [4] Based on serology, the positivity rate was 13% in asymptomatic SARS 4% in those with mild symptoms, and 82% in those with severe disease [5]. Since the emergence of SARS-COV-2, (known initially as 2019-nCoV), in Wuhan, China, in December 2019, the number of global cases had increased significantly. [...]studies will enhance the understanding of the pathogenesis of these emerging viruses and will inform policy makers to make scientifically sound recommendations.Funding source None.CRediT authorship contribution statement Jaffar A. Al-Tawfiq: Conceptualization, Writing - original draft.Declaration of competing interest None.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>32114075</pmid><doi>10.1016/j.tmaid.2020.101608</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1477-8939
ispartof Travel medicine and infectious disease, 2020-05, Vol.35, p.101608-101608, Article 101608
issn 1477-8939
1873-0442
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7102602
source Elsevier
subjects Betacoronavirus
Coronavirus Infections
Coronaviruses
COVID-19
Disease transmission
Families & family life
Humans
Infections
Infectious diseases
Middle East respiratory syndrome
Middle East Respiratory Syndrome Coronavirus
Pandemics
Pathogens
Pneumonia, Viral
Respiratory diseases
SARS Virus
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Symptoms
Travel medicine
Viruses
title Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A07%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Asymptomatic%20coronavirus%20infection:%20MERS-CoV%20and%20SARS-CoV-2%20(COVID-19)&rft.jtitle=Travel%20medicine%20and%20infectious%20disease&rft.au=Al-Tawfiq,%20Jaffar%20A.&rft.date=2020-05-01&rft.volume=35&rft.spage=101608&rft.epage=101608&rft.pages=101608-101608&rft.artnum=101608&rft.issn=1477-8939&rft.eissn=1873-0442&rft_id=info:doi/10.1016/j.tmaid.2020.101608&rft_dat=%3Cproquest_pubme%3E2425684896%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c553t-f8a7f3d6d662713e6911895f20ceb61804991583b7454071032fca1577acaced3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2425684896&rft_id=info:pmid/32114075&rfr_iscdi=true